Biosimilars Charge the Market But Still Face Many Hurdles.
Thomas
T
Reinke
D059451:Biosimilar Pharmaceuticals / Q000191:economics*; D003362:Cost-Benefit Analysis; D007880:Legislation, Drug; D008329:Managed Care Programs; D011050:Policy Making; D014481:United States; D014486:United States Food and Drug Administration
D059451:Biosimilar Pharmaceuticals